Hematologic Malignancy
Classic Hodgkin Lymphoma
CI-CAN-00002375CHLExplore in graph →
Hematologic41 active trials3 approved drugs
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002375CHLExplore in graph →
Clinical trials
114 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02940301 | Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 18 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04561206 | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | recruiting | Phase 2 | 31 | City of Hope Medical CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | active not recruiting | Phase 2 | 83 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05934084 | Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors | recruiting | N/A | 552 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06745076 | Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma | recruiting | Phase 2 | 125 | University of WashingtonOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05039073 | Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors | recruiting | Phase 2 | 46 | Emory UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04288726 | Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas | active not recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05705531 | A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | recruiting | — | 190 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT03150329 | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | active not recruiting | Phase 1 | 52 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07021989 | ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 38 | Michael Spinner, MDOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07275216 | Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | recruiting | Phase 2 | 23 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03907488 | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | active not recruiting | Phase 3 | 994 | National Cancer Institute (NCI)NIH | 3 | Aug 4, 2026 | clinicaltrials |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | active not recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 3 | Jul 29, 2026 | clinicaltrials |
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07720011 | Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma | completed | Phase 2 | 130 | Peking University People's HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06164275 | Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07572123 | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 374 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT06377540 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | recruiting | Phase 2 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04788043 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | terminated | Phase 2 | 8 | Ranjana AdvaniOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03697408 | Itacitinib + Everolimus in Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of PennsylvaniaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04510636 | Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07652476 | Neurocognitive Assessment in Long-Term Survivors of Lymphoma(FIL_LymDeCo) | not yet recruiting | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05162976 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | active not recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06822855 | Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma(LH_BIO) | recruiting | — | 755 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT01476410 | Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma | completed | Phase 2 | 49 | Northwestern UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07575893 | CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma(REACH-CD30) | not yet recruiting | Phase 1 | 12 | New York Medical CollegeOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT05404945 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | active not recruiting | Phase 2 | 24 | University of VirginiaOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03580564 | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 109 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT03057795 | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma | active not recruiting | Phase 2 | 62 | City of Hope Medical CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05949931 | Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma | recruiting | Phase 2 | 108 | Sun Yat-sen UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06617286 | CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 21 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT02684708 | Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents | completed | Phase 3 | 2,921 | University of GiessenOTHER | 19 | Mar 31, 2026 | clinicaltrials |
| NCT06563245 | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | recruiting | Phase 2 / Phase 3 | 96 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03652441 | Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 14 | University of CologneOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04486391 | Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | terminated | Phase 3 | 3 | BeiGeneINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04067037 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | active not recruiting | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 2, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT07356882 | European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma(EURHOLY) | recruiting | — | 400 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02815137 | Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma(XPO1) | completed | N/A | 137 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04074746 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | completed | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT04318080 | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma(TIRHOL) | completed | Phase 2 | 46 | BeiGeneINDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT07171827 | Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma | completed | N/A | 60 | Helwan UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials